Long-Term Management Strategies of EGFR-Mutant mNSCLC

This segment addresses long-term management considerations for patients receiving combination therapy for EGFR-mutant mNSCLC. Experts emphasize shared decision-making as central to therapy planning, highlighting the importance of aligning treatment choices with patient goals, preferences, and quality-of-life priorities. The panel discusses the typical course of therapy, noting that first-line interventions have the greatest impact on survival, whereas second- and third-line options are more limited and less effective. They detail practical considerations for therapy administration, including intravenous versus oral regimens, and stress the importance of educating patients about the survival benefits of combination therapy compared to single-agent oral therapy. Clinical data demonstrate that combination regimens, such as amivantamab plus lazertinib, achieve longer progression-free survival and overall survival than monotherapy, justifying upfront intensity despite the added logistical burden. The panel also highlights the importance of monitoring for adverse events, managing dermatologic and systemic side effects, and maintaining therapeutic relationships to ensure adherence and patient satisfaction. Strategies for dose adjustment and therapy de-escalation are addressed, emphasizing individualized assessment and ongoing evaluation of both objective response and patient-reported outcomes. This segment reinforces that thoughtful planning, proactive monitoring, and patient education are essential for optimizing long-term outcomes and maximizing the benefit of combination therapies.